Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer

被引：13

作者：

Aminkeng, Folefac ^{[2
,3
]}

Ross, Colin J. D. ^{[4
]}

Rassekh, Shahrad R. ^{[3
,5
]}

Rieder, Michael J. ^{[6
]}

Bhavsar, Amit P. ^{[4
]}

Sanatani, Shubhayan ^{[3
]}

Bernstein, Daniel ^{[7
]}

Hayden, Michael R. ^{[2
,3
,8
]}

Amstutz, Ursula ^{[9
,10
]}

Carleton, Bruce C. ^{[1
,3
]}

机构：

[1] Univ British Columbia, Dept Pediat, Div Translat Therapeut, 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada

[2] Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC, Canada

[3] Univ British Columbia, BC Childrens Hosp Res Inst, Vancouver, BC, Canada

[4] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada

[5] Univ British Columbia, Dept Pediat, Div Pediat Hematol Oncol BMT, Vancouver, BC, Canada

[6] Univ Western Ontario, Dept Pediat, London, ON, Canada

[7] Stanford Univ, Dept Pediat, Div Cardiol, Stanford, CA 94305 USA

[8] Teva Pharmaceut Ind, Petah Tiqwa, Israel

[9] Inselspital Bern Univ Hosp, Univ Inst Clin Chem, Bern, Switzerland

[10] Univ Bern, Bern, Switzerland

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2017年 / 83卷 / 05期

关键词：

anthracycline; anthracycline-induced cardiotoxicity; cancer; chemotherapy; clinical practice guidelines; congestive heart failure; pharmacogenomic screening; DOXORUBICIN-INDUCED CARDIOTOXICITY; RECOMMENDATIONS; UGT1A6; IDENTIFICATION; REACTIVITY; METABOLITE; TOXICITY; CHILDREN; GRADE; CELLS;

D O I：

10.1111/bcp.13218

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1143 / 1145

页数：3

共 17 条

[1] Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity [J].

Aminkeng, Folefac ;

Ross, Colin J. D. ;

Rassekh, Shahrad R. ;

Hwang, Soomi ;

Rieder, Michael J. ;

Bhavsar, Amit P. ;

Smith, Anne ;

Sanatani, Shubhayan ;

Gelmon, Karen A. ;

Bernstein, Daniel ;

Hayden, Michael R. ;

Amstutz, Ursula ;

Carleton, Bruce C. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (03) :683-695

[2] A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer [J].

Aminkeng, Folefac ;

Bhavsar, Amit P. ;

Visscher, Henk ;

Rassekh, Shahrad R. ;

Li, Yuling ;

Lee, Jong W. ;

Brunham, Liam R. ;

Caron, Huib N. ;

van Dalen, Elvira C. ;

Kremer, Leontien C. ;

van der Pal, Helena J. ;

Amstutz, Ursula ;

Rieder, Michael J. ;

Bernstein, Daniel ;

Carleton, Bruce C. ;

Hayden, Michael R. ;

Ross, Colin J. D. .

NATURE GENETICS, 2015, 47 (09) :1079-+

[3] Genetic determinants of anthracycline cardiotoxicity - ready for the clinic? [J].

Craig, Lauren A. ;

Ekert, Paul G. ;

Conyers, Rachel ;

Elliott, David A. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) :1141-1142

[4] Common Regulatory Variation Impacts Gene Expression in a Cell Type-Dependent Manner [J].

Dimas, Antigone S. ;

Deutsch, Samuel ;

Stranger, Barbara E. ;

Montgomery, Stephen B. ;

Borel, Christelle ;

Attar-Cohen, Homa ;

Ingle, Catherine ;

Beazley, Claude ;

Arcelus, Maria Gutierrez ;

Sekowska, Magdalena ;

Gagnebin, Marilyne ;

Nisbett, James ;

Deloukas, Panos ;

Dermitzakis, Emmanouil T. ;

Antonarakis, Stylianos E. .

SCIENCE, 2009, 325 (5945) :1246-1250

[5] GRADE:: going from evidence to recommendations [J].

Guyatt, Gordon H. ;

Oxman, Andrew D. ;

Kunz, Regina ;

Falck-Ytter, Yngve ;

Vist, Gunn E. ;

Liberati, Alessandro ;

Schunemann, Holger J. .

BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7652) :1049-1051

[6] GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations [J].

Guyatt, Gordon H. ;

Oxman, Andrew D. ;

Vist, Gunn E. ;

Kunz, Regina ;

Falck-Ytter, Yngve ;

Alonso-Coello, Pablo ;

Schuenemann, Holger J. .

BRITISH MEDICAL JOURNAL, 2008, 336 (7650) :924-926

[7] UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S) [J].

Krishnaswamy, S ;

Hao, Q ;

Al-Rohaimi, A ;

Hesse, LM ;

von Moltke, LL ;

Greenblatt, DJ ;

Court, MH .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) :1340-1346

[8] Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes [J].

Maillet, Agnes ;

Tan, Kim ;

Chai, Xiaoran ;

Sadananda, Singh N. ;

Mehta, Ashish ;

Ooi, Jolene ;

Hayden, Michael R. ;

Pouladi, Mahmoud A. ;

Ghosh, Sujoy ;

Shim, Winston ;

Brunham, Liam R. .

SCIENTIFIC REPORTS, 2016, 6

[9] Anthracycline metabolism and toxicity in human myocardium: Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite [J].

Minotti, G ;

Licata, S ;

Saponiero, A ;

Menna, P ;

Calafiore, AM ;

Di Giammarco, G ;

Liberi, G ;

Animati, F ;

Cipollone, A ;

Manzini, S ;

Maggi, CA .

CHEMICAL RESEARCH IN TOXICOLOGY, 2000, 13 (12) :1336-1341

[10] Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells [J].

Nagar, S ;

Zalatoris, JJ ;

Blanchard, RL .

PHARMACOGENETICS, 2004, 14 (08) :487-499

← 1 2 →